Annovis Bio (NYSE: ANVS) announced a collaboration with Weave Bio to support preparation of its planned New Drug Application (NDA) for buntanetap, an investigational oral therapy for neurodegenerative diseases including Alzheimer's disease (AD) and Parkinson's disease (PD). The company will use the Weave AI platform to draft, review, and manage NDA documents, while its regulatory and clinical teams retain responsibility for content, verification, and final approval of all documents submitted to the U.S. Food and Drug Administration (FDA).
The collaboration follows the completion of enrollment in Annovis's pivotal Phase 3 AD study, which enrolled 862 biomarker-confirmed patients, exceeding the original target of 760. Annovis aims to achieve database lock for the six-month treatment period in December 2026, followed by top-line symptomatic data in March 2027, with the company seeking to have most of the NDA prepared before the data readout.
This news matters because it signals a potentially faster and more efficient path to regulatory submission for a therapy that could address the underlying causes of neurodegeneration. By using AI to manage the complex NDA process, Annovis may reduce the time and resources required to prepare a filing, potentially bringing buntanetap to patients sooner if approved. For investors, the collaboration highlights Annovis's proactive approach to regulatory strategy, which could enhance the company's value proposition in the competitive biotech landscape.
Buntanetap is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients.
Annovis Bio, headquartered in Malvern, Pennsylvania, is a Phase 3 clinical-stage biotechnology company. For more information, visit www.annovisbio.com and follow the company on LinkedIn. The latest news and updates relating to ANVS are available in the company's newsroom at https://ibn.fm/ANVS.
About BioMedWire
BioMedWire ("BMW") is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled recognition and brand awareness. BMW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.BioMedWire.com. Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer.
